Dr. Wiseman has 30 years of experience in drug discovery research in the pharmaceutical industry. He recently joined Edelweiss Connect as Senior Fellow in the team that is building computational tools to promote multiple facets of chemical safety – including toxicology, low environmental impact, and green manufacturing - in multiple industries  He previously held positions as worldwide vice president and member of the Research Executive Council of the pharmaceutical company GlaxoSmithKline and then as Chief Technology Officer at the biotechnology company Locus Pharmaceuticals. At Locus he participated in raising $32 MM in financing and established research collaborations valued at $60 MM. Most recently, he served for 10 years as Executive in Residence, Senior Research Scientist, and Adjunct Professor of Chemistry and Biochemistry at Ohio University. In these roles he conducted independent research on natural products as therapeutic agents and was responsible for identifying and advancing life science technologies to commercialization. These efforts advanced 5 companies to the pre-seed funding stage. Dr. Wiseman holds a B.S. degree summa cum laude in chemistry from Ohio University and a Ph.D. in chemistry from Harvard University, with postdoctoral studies in biochemistry at Stanford and Brandeis Universities. He retired from Ohio University in 2022.